Significant Ownership of Commodore Capital LP

Signature - Title
Michael Kramarz - Managing Partner
Location
New York, NY
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Commodore Capital LP.

Notify me when Commodore Capital LP files a new Schedule 13D/G report.

⭐ Subscribe ⭐

Significant Ownership of Commodore Capital LP

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ELVN Enliven Therapeutics, Inc. Common Stock, par value $0.001 per share 9.9% $124,554,751 6,022,957 Commodore Capital LP 30 Jun 2025
RLAY Relay Therapeutics, Inc. Common Stock, par value $0.0001 per share 9.9% $88,740,000 $19,053,000 17,000,000 +27.3% Commodore Capital LP 30 Sep 2025
ASMB ASSEMBLY BIOSCIENCES, INC. Common Stock, par value $0.001 9.9% $41,207,516 1,615,981 Commodore Capital LP 08 Aug 2025
SABS SAB BIOTHERAPEUTICS, INC. Common Stock, $0.0001 par value per share 9.9% $9,588,711 4,522,977 Commodore Capital LP 26 Sep 2025
PALI PALISADE BIO, INC. Common Stock, par value $0.01 per share 9.9% $5,620,586 9,690,665 Commodore Capital LP 01 Oct 2025
ANRO Alto Neuroscience, Inc. Common Stock, $0.0001 par value per share 9.8% $12,826,149 3,190,267 Commodore Capital LP 20 Oct 2025
COGT Cogent Biosciences, Inc. Common Stock, $0.001 Par Value 7.2% $146,587,742 $54,568,000 10,208,060 +59.3% Commodore Capital LP 30 Sep 2025
DRUG Bright Minds Biosciences Inc. Common Shares, without par value 7.2% $18,035,000 500,000 COMMODORE CAPITAL LP 31 Dec 2024
TERN Terns Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share 6.5% $42,807,000 $7,885,500 5,700,000 +22.6% Commodore Capital LP 30 Sep 2025
TYRA Tyra Biosciences, Inc. Common Stock, $0.0001 par value per share 6.3% $47,216,925 $8,743,875 3,375,000 +22.7% Commodore Capital LP 30 Sep 2025
LB PHARMACEUTICALS INC Common Stock, $0.0001 par value per share 5.5% 1,225,000 Commodore Capital LP 11 Sep 2025
AMLX Amylyx Pharmaceuticals, Inc. Common Stock, $0.0001 par value per share 5.1% $89,213,500 5,650,000 Commodore Capital LP 10 Nov 2025
NRIX Nurix Therapeutics, Inc. Common Stock, par value $0.001 per share 4.9% $34,927,708 -$646,291 3,780,055 -1.8% Commodore Capital LP 30 Sep 2025
MRUS Merus N.V. Common Shares, (euro) 0.09 nominal value per share 4.7% $237,162,000 -$15,138,000 3,525,000 -6% Commodore Capital LP 30 Jun 2025
CLDX Celldex Therapeutics, Inc. Common Stock, par value $.001 4.6% $78,343,026 -$8,321,473 3,028,335 -9.6% Commodore Capital LP 30 Sep 2025
VRDN Viridian Therapeutics, Inc.\DE Common Stock, $0.01 par value 3.9% $69,056,000 -$23,738,000 3,200,000 -25.6% Commodore Capital LP 30 Sep 2025
NGNE Neurogene Inc. Common Stock, $0.000001 par value 3% $8,060,995 427,866 Commodore Capital LP 30 Jun 2025
CELC Celcuity Inc. Common Stock, $0.001 par value per share 2.9% $8,995,286 1,095,650 COMMODORE CAPITAL LP 31 Dec 2024
CDTX Cidara Therapeutics, Inc. Common Stock, par value $0.0001 per share 2% $56,019,600 -$56,498,400 585,000 -50.2% Commodore Capital LP 30 Sep 2025
NKTX Nkarta, Inc. Common Stock, $0.0001 par value per share 0.5% $548,883 351,848 COMMODORE CAPITAL LP 31 Dec 2024
SLDB Solid Biosciences Inc. Common Stock $0.001 par value per share 0% $0 -$33,785,000 0 -100% Commodore Capital LP 30 Jun 2025
CRDF Cardiff Oncology, Inc. Common Stock 0% $0 -$11,200,001 0 -100% Commodore Capital LP 30 Jun 2025

Schedules 13D/G Reported by Commodore Capital LP:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.